Loading...
Loading...
In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on
Albany Molecular ResearchAMRI, and raised the price target from $19.00 to $21.00.
In the report, Morgan Stanley noted, “Following recent OsoBio acq. we update ests & raise PT to $21. With M&A strategy tracking ahead of expectations, we have increased confidence in bull case unfolding & highlight AMRI as a top pick in our coverage for 2H14.”
Albany Molecular Research closed on Tuesday at $17.44.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in